From left: Mr. Jean-Luc Butel, Corporate Vice President and President, International (Baxter), Mr. Yeoh Keat Chuan, Managing Director EDB, Mr. Kirk Wagar, US Ambassador to Singapore and Mr. Joerg Ahlgrimm, Vice President, Global Operations, Bioscience (Baxter).
Opening of Baxter Bioscience Facility in Singapore7 August 2014
On 7 August 2014, Baxter International Inc. announced the formal opening of its first advanced recombinant biologic production facility in Singapore, including its investment in a new multi-product recombinant protein manufacturing suite. The current production suite supports the manufacturing of ADVATE, a leading drug used worldwide for the treatment of haemophilia A patients.
The second suite will initially produce RIXUBIS, a protein for the treatment of haemophilia B patients and, when operational, will be the primary global commercial manufacturing facility. The 14,000m2 (built-up area) biologics manufacturing facility in Singapore currently employs 400 production staff and expects to hire up to 450 by 2015 to support the second production suite.
Speaking at the opening of the facility, Mr Jean-Luc Butel, Corporate Vice President and President of Baxter’s International Operations said: “The opening of the Singapore facility is a reflection of the company’s commitment. Baxter is grateful to the Singapore Economic Development Board of Singapore for their support in establishing this facility and for its commitment to collaborations that advance access to quality healthcare.”
Mr Yeoh Keat Chuan, Managing Director at the Singapore Economic Development Board, said there are currently nine biologics facility in Singapore which employ over 2,000 people. And the government will continue to support this “important growth area” by investing in talent development, supporting infrastructure and new technologies.
“Baxter’s expansion of its biologics footprint in Singapore reinforces our position as a leading biologics hub,” said Mr Yeoh.
7 August 2014
Press Release and Speech